Back to Search Start Over

Remdesivir or Nirmatrelvir/Ritonavir Therapy for Omicron SARS-CoV-2 Infection in Hematological Patients and Cell Therapy Recipients

Authors :
Piñana, José Luis
Heras, Inmaculada
Aiello, Tommaso Francesco
García-Cadenas, Irene
Vázquez, Lourdes
López Jiménez, Javier
Chorão, Pedro
Aroca, Cristina
García-Vidal, Carolina
Arroyo, Ignacio
Soler-Espejo, Eva
López-Corral, L.
Avendaño, Alejandro
Arrufat, Anna
García-Gutierrez, V.
Arellano, Elena
Hernández-Medina, Lorena
González-Santillana, Clara
Morell, Julia
Hernández-Rivas, José Ángel
Rodriguez-Galvez, Paula
Mico-Cerdá, Mireia
Guerreiro, Manuel
Campos, Diana
Navarro, David
Cedillo, Ángel
Martino, Rodrigo
Solano, Carlos
Piñana, José Luis
Heras, Inmaculada
Aiello, Tommaso Francesco
García-Cadenas, Irene
Vázquez, Lourdes
López Jiménez, Javier
Chorão, Pedro
Aroca, Cristina
García-Vidal, Carolina
Arroyo, Ignacio
Soler-Espejo, Eva
López-Corral, L.
Avendaño, Alejandro
Arrufat, Anna
García-Gutierrez, V.
Arellano, Elena
Hernández-Medina, Lorena
González-Santillana, Clara
Morell, Julia
Hernández-Rivas, José Ángel
Rodriguez-Galvez, Paula
Mico-Cerdá, Mireia
Guerreiro, Manuel
Campos, Diana
Navarro, David
Cedillo, Ángel
Martino, Rodrigo
Solano, Carlos
Publication Year :
2023

Abstract

Background: Scarce data exist that analyze the outcomes of hematological patients with SARS-CoV-2 infection during the Omicron variant period who received treatment with remdesivir or nirmatrelvir/ritonavir. Methods: This study aims to address this issue by using a retrospective observational registry, created by the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group, spanning from 27 December 2021 to 30 April 2023. Results: This study included 466 patients, 243 (52%) who were treated with remdesivir and 223 (48%) with nirmatrelvir/ritonavir. Nirmatrelvir/ritonavir was primarily used for mild cases, resulting in a lower COVID-19-related mortality rate (1.3%), while remdesivir was preferred for moderate to severe cases (40%), exhibiting a higher mortality rate (9%). A multivariate analysis in the remdesivir cohort showed that male gender (odds ratio (OR) 0.35, p = 0.042) correlated with a lower mortality risk, while corticosteroid use (OR 9.4, p < 0.001) and co-infection (OR 2.8, p = 0.047) were linked to a higher mortality risk. Prolonged virus shedding was common, with 52% of patients shedding the virus for more than 25 days. In patients treated with remdesivir, factors associated with prolonged shedding included B-cell malignancy as well as underlying disease, severe disease, a later onset of and shorter duration of remdesivir treatment and a higher baseline viral load. Nirmatrelvir/ritonavir demonstrated a comparable safety profile to remdesivir, despite a higher risk of drug interactions. Conclusions: Nirmatrelvir/ritonavir proved to be a safe and effective option for treating mild cases in the outpatient setting, while remdesivir was preferred for severe cases, where corticosteroids and co-infection significantly predicted worse outcomes. Despite antiviral therapy, prolonged shedding remains a matter of concern.

Details

Database :
OAIster
Notes :
English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1431966857
Document Type :
Electronic Resource